History of Research on Tumor Angiogenesis [electronic resource] / by Domenico Ribatti.

Ribatti, Domenico.
Call Number
614.5999
Author
Ribatti, Domenico. author.
Title
History of Research on Tumor Angiogenesis by Domenico Ribatti.
Physical Description
X, 126 p. online resource.
Summary
In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors.
Added Author
SpringerLink (Online service)
Subject
MEDICINE.
HISTORY.
CANCER RESEARCH.
ONCOLOGY.
PATHOLOGY.
CELL BIOLOGY.
Biomedicine.
Cancer Research.
Oncology.
History of Science.
Pathology.
Cell Biology.
Multimedia
  • Libraries with this item
Total Ratings: 0
No records found to display.
 
 
 
03044nam a22005175i 4500
001
 
 
vtls001568276
003
 
 
VRT
005
 
 
20170831182500.0
007
 
 
cr nn 008mamaa
008
 
 
170831s2009    ne |    s    |||| 0|eng d
020
$a 9781402095634 $9 978-1-4020-9563-4
024
7
$a 10.1007/978-1-4020-9563-4 $2 doi
035
$a (DE-He213)978-1-4020-9563-4
039
9
$a 201708311825 $b santha $y 201708311319 $z vjs2012
050
4
$a RC261-271
072
7
$a MJCL $2 bicssc
072
7
$a MED062000 $2 bisacsh
082
0
4
$a 614.5999 $2 23
100
1
$a Ribatti, Domenico. $e author.
245
1
0
$a History of Research on Tumor Angiogenesis $h [electronic resource] / $c by Domenico Ribatti.
264
1
$a Dordrecht : $b Springer Netherlands, $c 2009.
300
$a X, 126 p. $b online resource.
336
$a text $b txt $2 rdacontent
337
$a computer $b c $2 rdamedia
338
$a online resource $b cr $2 rdacarrier
347
$a text file $b PDF $2 rda
520
$a In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors.
650
0
$a MEDICINE.
650
0
$a HISTORY.
650
0
$a CANCER RESEARCH.
650
0
$a ONCOLOGY.
650
0
$a PATHOLOGY.
650
0
$a CELL BIOLOGY.
650
1
4
$a Biomedicine.
650
2
4
$a Cancer Research.
650
2
4
$a Oncology.
650
2
4
$a History of Science.
650
2
4
$a Pathology.
650
2
4
$a Cell Biology.
710
2
$a SpringerLink (Online service)
773
0
$t Springer eBooks
776
0
8
$i Printed edition: $z 9781402095597
856
4
0
$u http://dx.doi.org/10.1007/978-1-4020-9563-4
912
$a ZDB-2-SBL
950
$a Biomedical and Life Sciences (Springer-11642)
999
$a VIRTUA               
No Reviews to Display
Summary
In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors.
Subject
MEDICINE.
HISTORY.
CANCER RESEARCH.
ONCOLOGY.
PATHOLOGY.
CELL BIOLOGY.
Biomedicine.
Cancer Research.
Oncology.
History of Science.
Pathology.
Cell Biology.
Multimedia